MTCO1P30

Across TCGA pan-cancer cohorts, MTCO1P30 RNA is linked to patient survival in 18 of 34 cancer types, making it the most broadly survival-associated MTCO1P30 data layer.

The strongest signal is observed in liver hepatocellular carcinoma (LIHC), where higher MTCO1P30 RNA is associated with worse disease-free survival. In most high-consensus cancer types, elevated MTCO1P30 expression acts as an unfavorable survival marker, although some lineages such as UCS and COAD show a favorable association.

LIHC, UCS, and COAD are the cancer types where MTCO1P30 RNA most reproducibly stratifies survival.

RNA survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
LIHC	DFS	Tertile	All	0.334	0.480	<.001	45	view →
UCS	DFS	Median	IV	0.952	0.473	.018	40	view →
COAD	DFS	Quartile	IV	0.768	0.376	.003	33	view →
READ	OS	Tertile	All	0.943	0.342	<.001	31	view →
LGG	DFS	Median	All	0.759	0.902	<.001	24	view →
THYM	DFS	Tertile	II,III,IV	1.000	0.562	.006	18	view →
UCEC	OS	Quartile	III,IV	0.832	0.519	.016	18	view →
PRAD	OS	Quartile	All	0.829	0.972	.003	18	view →
DLBC	DFS	Median	All	0.589	0.896	.006	13	view →
UVM	OS	Tertile	All	0.894	0.414	.041	12	view →
LUSC	OS	Quartile	All	0.760	0.625	.010	12	view →
LUAD	OS	Median	III,IV	0.396	0.209	.022	10	view →

Pink = unfavorable, green = favorable. Showing the 12 strongest of 18 lineages.

MTCO1P30–LIHC (DFS)

Open the LIHC breakdown →